Claims for Patent: 7,846,427

Summary for Patent: 7,846,427

Title:	Stabilized interferon liquid formulations
Abstract:	Stabilized liquid pharmaceutical composition comprising an interferon (IFN) or an isoform, mutein, fused protein, functional derivative, active fraction or salt thereof, wherein said formulation is a solution that comprises a buffer, a cyclodextrin, an isotonicity agent and an anti-oxidant are described here. Preferably the interferon is interferon beta-1a and the cyclodextrin is HPBCD. These formulations are stable at room temperature, thus bringing the advantage of lower costs for formulation storage and increased safety for the patient with respect to possible \"errors\" during handling. As a matter of fact, having such formulations stable at room temperature reduces the risk of formation of degradation products potentially responsible for adverse events (e.g. immunogenicity).
Inventor(s):	Del Curto; Maria Dorly (Corvino San Quicico, IT)
Assignee:	Ares Trading S.A. (Aubonne, CH)
Application Number:	10/582,027
Patent Claims:	1. A stabilized liquid pharmaceutical composition comprising an interferon (IFN) or salt thereof, a buffer, 2-hydroxypropyl-beta-cyclodextrin ("HPBCD"), an isotonicity agent and an anti-oxidant, wherein said HPBCD is present at about a 500-fold to about a 700-fold molar excess with respect to said interferon. 2. The composition according to claim 1, wherein said interferon is IFN-beta. 3. The composition according to claim 2, wherein said IFN-beta is recombinant human IFN-beta. 4. The composition according to claim 1, wherein said buffer is present in an amount sufficient to maintain the pH of said composition within plus or minus 0.5 units of a specified pH, where the specified pH is about 3 to about 6. 5. The composition according to claim 4, wherein said pH is 3.8. 6. The composition according to claim 1, wherein said buffer is present at a concentration of about 5 mM to 500 mM. 7. The composition according to claim 6, wherein said buffer is present at a concentration of about 50 mM. 8. The composition according to claim 1, wherein the buffer is acetate buffer. 9. The composition according to claim 1, wherein said isotonicity agent is mannitol. 10. The composition according to claim 1, wherein said isotonicity agent is present at a concentration of about 0.5 mg/ml to about 500 mg/ml. 11. The composition according to claim 10, wherein said isotonicity agent is present at a concentration of about 50 mg/ml. 12. The composition according to claim 1, wherein said antioxidant is methionine. 13. The composition according to claim 1, wherein said antioxidant is present at a concentration of about 0.01 to about 5 mg/ml. 14. The composition according to claim 13, wherein said antioxidant is present at a concentration of about 0.1 mg/ml. 15. The composition according to claim 1, wherein said interferon is present at a concentration of about 10 .mu.g/ml to about 800 .mu.g/ml. 16. The composition according to claim 1, wherein said interferon is present at a concentration of about 44 .mu.g/ml. 17. The composition according to claim 1, wherein said interferon is present at a concentration of about 88 .mu.g/ml. 18. The composition according to claim 1, wherein said interferon is present at a concentration of about 276 .mu.g/ml. 19. The composition according to claim 1, wherein said composition is an aqueous solution. 20. The composition according to claim 1, further comprising a bacteriostatic agent. 21. The composition according to claim 20, wherein said bacteriostatic agent is benzyl alcohol. 22. The composition according to claim 20, wherein said bacteriostatic agent is present at a concentration of about 0.1% to about 2%. 23. The composition according to claim 20, wherein said bacteriostatic agent is present at a concentration of about 0.2 or 0.3%. 24. The composition according to claim 1, wherein the isotonicity agent is mannitol, the anti-oxidant is methionine and the interferon is interferon beta. 25. An article of manufacture comprising the composition of claim 1 in a container. 26. An article of manufacture comprising a container containing a stabilized liquid pharmaceutical composition comprising: (a) an interferon (IFN) or a salt thereof, wherein said composition is a solution that comprises a buffer, 2-hydroxypropyl-beta-cyclodextrin, an isotonicity agent and an anti-oxidant, wherein said cyclodextrin is present at a molar ratio vs. interferon of from 500-fold molar excess up to 700-fold molar excess; or (b) a composition comprising an interferon (IFN) or a salt thereof, wherein said composition is a solution that comprises a buffer, 2-hydroxypropyl-beta-cyclodextrin, an isotonicity agent and an anti-oxidant, wherein said composition comprises the following components in an acetate buffer: TABLE-US-00011 Interferon-beta-1a 44 .mu.g/mL HPBCD 1.9 mg/mL Methionine 0.1 mg/mL Mannitol 50 mg/mL; and wherein said container is hermetically sealed in conditions that are sterile and appropriate for storage prior to use. 27. The article of manufacture according to claim 26, wherein said container is for mono-dose administration. 28. The article of manufacture according to claim 27, wherein said container is a pre-filled syringe for mono-dose administration. 29. The article of manufacture according to claim 27, wherein said container is a vial. 30. The article of manufacture according to claim 27, wherein said container is a cartridge for an auto-injector. 31. The article of manufacture according to claim 26, wherein said article of manufacture is a kit for multi-dose administration of a pharmaceutical composition, said kit comprising a first container, said first container comprising a container containing said stabilized liquid pharmaceutical composition and a second container filled with a solution of a bacteriostatic agent. 32. The article of manufacture according to claim 26, wherein said container is for multidose administration. 33. A composition comprising the following components in an acetate buffer: TABLE-US-00012 Interferon beta-1a 44 .mu.g/mL HPBCD 1.9 mg/mL Methionine 0.1 mg/mL Mannitol 50 mg/mL. 34. The composition according to claim 33, wherein the composition consists of the following components in an acetate buffer: TABLE-US-00013 Interferon beta-1a 44 .mu.g/mL HPBCD 1.9 mg/mL Methionine 0.1 mg/mL Mannitol 50 mg/mL. 35. An article of manufacture comprising the composition of claim 34 in a container.

Details for Patent 7,846,427

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Biogen Inc.	AVONEX	interferon beta-1a	For Injection	103628	05/17/1996		2023-12-11
Biogen Inc.	AVONEX	interferon beta-1a	Injection	103628	05/28/2003		2023-12-11
Biogen Inc.	AVONEX	interferon beta-1a	Injection	103628	02/27/2012		2023-12-11
Emd Serono, Inc.	REBIF	interferon beta-1a	Injection	103780	03/07/2002		2023-12-11
Emd Serono, Inc.	REBIF	interferon beta-1a	Injection	103780	12/17/2004		2023-12-11